Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

<p>Table S2: Sequence information for probes and primers used in this article.</p>

保存先:

書誌詳細
第一著者:	Nan Ding (15321526) (author)
その他の著者:	A-Bin You (15321529) (author), Hu Yang (15321532) (author), Guo-Sheng Hu (15321535) (author), Chun-Ping Lai (15321538) (author), Wen Liu (12209560) (author), Feng Ye (15321541) (author)
出版事項:	2025
主題:	Cancer Cancer Risk Factors Cancer Biology Molecular and Cellular Biology Immuno-oncology Epigenetics Gastrointestinal Cancers Colorectal cancer Immunology Immunomodulation Oncogenes & Tumor Suppressors Tumor suppressor genes
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
著者:: Nan Ding (15321526)
出版事項: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
著者:: Cheng-Kai Wang (14963880)
出版事項: (2025)

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
著者:: Christopher T. Letson (16424095)
出版事項: (2025)

Figure S.1 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.2 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.3 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.4 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.5 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.6 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.7 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Figure S.8 from Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression
著者:: Xufeng Lu (14960724)
出版事項: (2025)

Supplementary table S5 from HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer
著者:: Penglin Pan (14959703)
出版事項: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
著者:: Yun-Guang Hong (14960966)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
著者:: Long Jiang (14956159)
出版事項: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
著者:: Smruthy Sivakumar (15053536)
出版事項: (2025)

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
著者:: Namhee Kim (14963603)
出版事項: (2025)

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
著者:: Namhee Kim (14963603)
出版事項: (2025)

Table S1 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
著者:: Lenka Stolarova (16547259)
出版事項: (2025)

Table S2 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
著者:: Lenka Stolarova (16547259)
出版事項: (2025)

Table S3 from ENIGMA <i>CHEK2</i>gether Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk
著者:: Lenka Stolarova (16547259)
出版事項: (2025)

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
著者:: Junfeng Xu (16437141)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_sqp6eumu2ug3kvn5sk7r33t3qg